Healthcare
•3753 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3753)
| Company | Market Cap | Price |
|---|---|---|
|
GKOS
Glaukos Corporation
Glaukos directly manufactures ophthalmology devices, including iStent MIGS implants used in eye surgeries.
|
$6.90B |
$120.30
+5.08%
|
|
MRUS
Merus N.V.
Company develops multispecific antibody therapeutics for oncology, including lead candidates like petosemtamab and BIZENGRI.
|
$6.81B |
$90.00
|
|
RYTM
Rhythm Pharmaceuticals, Inc.
Rhythm's core business is developing and commercializing therapies for ultra-rare diseases (e.g., setmelanotide for MC4R pathway deficiencies, BBS), a hallmark of rare-disease biotech.
|
$6.75B |
$101.67
-4.14%
|
|
PRAX
Praxis Precision Medicines, Inc.
Praxis's Cerebrum platform develops oral small-molecule CNS therapies (e.g., ulixacaltamide, Vormatrigine).
|
$6.68B |
$317.17
+6.52%
|
|
CHE
Chemed Corporation
Chemed's VITAS Hospice provides direct home health and hospice care services.
|
$6.58B |
$452.49
-1.40%
|
|
MIR
Mirion Technologies, Inc.
Core business: Mirion designs and manufactures medical devices and biometric sensing equipment used in radiology, radiation therapy, and nuclear medicine.
|
$6.30B |
$26.94
-0.22%
|
|
BLCO
Bausch + Lomb Corporation
Ophthalmology Devices – direct manufacture and sale of eye-care surgical devices and related ophthalmic equipment.
|
$6.07B |
$17.18
-1.49%
|
|
PCVX
Vaxcyte, Inc.
PCVX directly develops and is advancing vaccine products (VAX-24, VAX-31) including pneumococcal conjugate vaccines, making Vaccines the core investable product category.
|
$6.05B |
$46.60
-3.00%
|
|
STVN
Stevanato Group S.p.A.
Directly manufactures Prefillable Syringes used for sterile biologic and small-molecule injections.
|
$5.98B |
$19.79
-5.76%
|
|
LTH
Life Time Group Holdings, Inc.
MIORA longevity clinics and other healthcare services are provided as part of the ecosystem.
|
$5.97B |
$27.14
+1.67%
|
|
OPCH
Option Care Health, Inc.
OPCH delivers home health infusion and hospice-related services in patients' homes, aligning with home health care offerings.
|
$5.85B |
$36.02
-0.24%
|
|
PTCT
PTC Therapeutics, Inc.
Sephience PKU and other PTC therapies are oral small-molecule drugs, a major product category for the company.
|
$5.76B |
$72.50
-4.14%
|
|
ESE
ESCO Technologies Inc.
Diagnostic Equipment reflects ESCO's diagnostic testing instruments and related software for measurement and monitoring.
|
$5.64B |
$218.44
-0.19%
|
|
CDTX
Cidara Therapeutics, Inc.
CD388 is an antiviral small-molecule therapeutic targeting neuraminidase for universal influenza prevention and treatment.
|
$5.61B |
$221.39
+0.00%
|
|
VNT
Vontier Corporation
Repair Solutions includes diagnostic equipment launches for vehicle repair workflows.
|
$5.56B |
$37.87
-2.60%
|
|
OLED
Universal Display Corporation
Contract research services via Adesis subsidiary.
|
$5.53B |
$116.22
-2.94%
|
|
RDNT
RadNet, Inc.
RadNet operates outpatient imaging centers/ASC, providing diagnostic imaging services.
|
$5.46B |
$70.94
-2.82%
|
|
SHC
Sotera Health Company
Nelson Labs provides outsourced microbiological and analytical chemistry testing plus regulatory advisory services.
|
$5.45B |
$19.18
-0.88%
|
|
COGT
Cogent Biosciences, Inc.
Cogent's lead asset bezuclastinib and the described pipeline assets are primarily oral small-molecule tyrosine kinase inhibitors, i.e., Oral Small Molecule Therapeutics.
|
$5.44B |
$38.92
-0.84%
|
|
IRTC
iRhythm Technologies, Inc.
Direct product: iRhythm's patch-based patient monitoring device and associated software for continuous cardiac monitoring.
|
$5.37B |
$167.37
-2.71%
|
|
UNMA
Unum Group 6.250% JR NT58
Disability insurance is a core component of Unum's financial protection offerings in workplace benefits.
|
$5.34B |
$23.58
-0.21%
|
|
CRNX
Crinetics Pharmaceuticals, Inc.
Crinetics develops oral, nonpeptide small-molecule therapeutics (lead platform) targeting GPCRs and related pipelines.
|
$5.27B |
$55.97
-0.82%
|
|
GNTX
Gentex Corporation
Medical Devices & Biometrics covers EyeLock iris biometrics and eSight medical device initiatives tied to Gentex's diversification.
|
$5.25B |
$23.94
-0.25%
|
|
ALKS
Alkermes plc
Direct product category encompassing Alkermes' oral small-molecule therapeutics, including LYBALVI.
|
$5.22B |
$31.62
+1.30%
|
|
IBRX
ImmunityBio, Inc.
Lead oncology-focused biotechnology with ANKTIVA and cancer immunotherapy platforms.
|
$5.22B |
$5.54
+40.13%
|
|
PTGX
Protagonist Therapeutics, Inc.
Direct product category: PTGX's core business is peptide therapeutics.
|
$5.10B |
$81.96
-3.29%
|
|
GPCR
Structure Therapeutics Inc.
Company focuses on developing oral small-molecule GPCR-targeted therapeutics, including lead GLP-1R agonist and other oral GPCR modulators.
|
$5.10B |
$88.70
+4.33%
|
|
UUUU
Energy Fuels Inc.
Radium/radioisotope recovery plans for targeted alpha therapy isotopes (radiopharmaceuticals).
|
$5.06B |
$21.96
+4.97%
|
|
GHC
Graham Holdings Company
Healthcare Services & Facilities reflecting CSI Pharmacy and patient services.
|
$4.98B |
$1140.96
-0.73%
|
|
KYMR
Kymera Therapeutics, Inc.
Kymera's core offering is oral small molecule therapeutics designed to degrade disease-causing proteins (STAT6, IRAK4, IRF5) in immunology indications.
|
$4.97B |
$69.52
-2.25%
|
|
BLTE
Belite Bio, Inc
Lead product Tinlarebant is an ophthalmic drug targeting retinal diseases (STGD1/GA).
|
$4.94B |
$155.06
+3.64%
|
|
OSIS
OSI Systems, Inc.
Patient Monitoring represents next-generation monitoring platforms and solutions within healthcare offerings.
|
$4.91B |
$292.48
+0.58%
|
|
PLXS
Plexus Corp.
Healthcare/Life Sciences end-market, with Plexus serving medical devices and related equipment through its engineering and manufacturing services.
|
$4.89B |
$181.56
+1.02%
|
|
TMDX
TransMedics Group, Inc.
TransMedics' Organ Care System (OCS) is a proprietary medical device platform for organ preservation and monitoring.
|
$4.89B |
$143.38
-0.22%
|
|
MMSI
Merit Medical Systems, Inc.
Directly tied to Merit's core cardiology/interventional devices, including cardiac intervention products and lead-management solutions (Cook acquisition).
|
$4.87B |
$82.33
+2.46%
|
|
CRSP
CRISPR Therapeutics AG
CRISPR-based ex vivo gene-editing therapy CASGEVY is a gene therapy product.
|
$4.87B |
$53.49
-1.32%
|
Showing page 7 of 38 (3753 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
